Evogene Ltd. — Investor Presentation 2017

Feb 6, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2017

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation for Investors – February 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: February 6, 2017

By: /s/ Alex Taskar

Alex Taskar Chief Financial Officer

——————————————

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1 A Slide Presentation for Investors – February 2017.

Exhibit 99.1

Introduction to Evogene February 2017 Ofer Haviv, President & CEO

Safe Harbor statement

This presentation contains "forward-looking to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or other matters regarding or affecting Frogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Act of 1995 (the "PSIRA"). Such forward-looking statements may be identified by the use of such words as "believe," "should," "planned," "estimated," "intend" or words of similar meaning. For these statements, Evogene claims the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, induding, without limitation, those described in our Periodical and Annual Reports, including our Registration Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are entirety by the previous statements. Except for any obligations information as required by applicable securities laws, Evogene disdains any obligation or commitment to update any information contained in this presentation or to publicy release the results of any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information ontained herein does not consitive a prospectus or other offering doument, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners there purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Table of contents

• Introduction ■
• Our technology .
• Applications and product programs
• · Summary of investment highlights

Introducing Evogene

Farmer's needs

The opportunity A dire need for innovation

1 Source: Phillips McDougall , 2016

2 Source: Phillips McDougall, 2015

2 Source: Research & Markets, 2016

Evogene 'at a glance'

• · An innovative, predictive discovery technology applied to identify:
  • · Genetic elements for improved seeds
  • · Chemical compounds for innovative Ag-Chemicals
  • · Microbes for novel Ag-Biologicals
• " Strategic collaborations with world-leading agriculture companies including BASF, Bayer, DuPont, Monsanto, Syngenta
• " Revenue model based on licensing agreements, which typically include three main revenue streams:
  • · R&D payments short term
  • · Milestone payments mid term
  • · Royalties from product sales longer term
• " Financial fundamentals -
  • · Cash position \$93 million (September 30th, 2016)
  • · Projected cash use for 2016 ~\$15 million
  • · Listed on TASE (2007) and NASDAQ (2013)

Our revenue & business models

MONSANTO 3 syngenta ロ・BASF (BAYER) QUPOND evogene 4 L2 Advanced development & Commercialization Discovery Early development registration RD R M Revenue model RD R&D payments · R&D funding by partner M · Additional payments received upon achieving predetermined objectives Milestone fees Royalties · Percentage of product sales by partner

Business model

Collaboration timeline

	Early collaboration model	" Collaboration prior to initiating product discovery and development activity
-1,2	Late collaboration models	Collaboration following internal product discovery and early development

evogene

Value creation per product program

Collaboration timeline

1 9

• Introduction ■
• Our technology .

Table of contents

• Applications and product programs
• · Summary of investment highlights

Technology platform

Plant validation systems

Technology platform

Table of contents

• Introduction
• Our technology .
• · Applications and product programs
• · Summary of investment highlights

Application pathways

lmproved seeds - market and unmet needs

Broad commercial potential for bringing 'breakthrough' traits to the seed market

* Source: Phillips McDougall , 2015

Improved seeds - activities and achievements

Overview

Product trait programs - focus on corn, soy, wheat, cotton and canola Traits Partners " Yield and abiotic stress - since 2004 biogemma Disease resistance - since 2007 Yield Insect resistance - since 2014 QU POND Main achievements -Abiotic stress MONSANTO Most advanced gene in Phase II of development " Collaborations with industry leaders Insect syngenta " Strong IP portfolio - over 4000 genes under patent protection resistance " Over 1000 genes under target crop validation by partners GLOBA Diseases resistance Example: Monsanto-Evogene collaboration MONSANTO Collaboration period - 8 years evogene Objective - improved seeds via biotechnology Gene discovery and trait Development and commercialization Crops - Corn, soybean, cotton, canola optimization Traits -

Computational

discovery

• · Yield, drought tolerance, fertilizer utilization
• Insect resistance-Fusarium resistance in corn

Key terms -

• " R&D and up-front payments total c.\$68M
• · Milestone payments + royalties from sales
• \$30M equity investment (including \$12M in IPO)

Model plant validation

and development

Target plant validation

Improved seeds - selected results

Improved seeds - upcoming value drivers

Improved

Application pathways

Innovative Ag-Chemicals - market and unmet needs

Innovative Ag-Chemicals - activities & achievements

Overview

Product programs -

" Novel herbicides with new Mode of Action (MOA) - since 2013

Main achievements -

• " Strategic collaboration with BASF (signed in 2015)
• Discovery and validation in plants of several novel herbicide targets
• Tens of discovered small molecules showing potential as active ingredient in novel herbicide

Innovative Ag-Chemicals - selected results

Innovative Ag-Chemicals - upcoming value drivers

Innovative Ag-Chemicals

Application pathways

1 25

Novel Ag-Biologicals - market and potential

Novel Ag-Biologicals - activities and achievements

Overview
Product programs -	Crops	X Product
Bio-stimulant (mainly yield and abiotic stress) in corn, soy and wheat - since 2015
Main achievements -		Bio-
10's of microbes showing consistent improvement of yield traits in greenhouse and field		stimulant
Establishment infrastructure for product research and development - computational, tailored OMIC experiments, plant assays, formulation and fermentation
2OK isolated microbes from unique sourcing samples, with > 10K sequenced 1

Internal Bio-stimulant discovery & development program

• Internal Evogene program including downstream activity
• License out to partner late collaboration model
• Expected time to product "5 years

genomes

Novel Ag-Biologicals - selected results

1 28

10's of microbial Hits displaying positive results in corn field trials

Evogene Announces Positive Field Trial Results in Ag-biologicals Program

November 16th, 2016

• Candidate microbial strains demonstrate positive efficacy and stability results in first year of field testing in corn under drought conditions

Rehovot, Israel - November 16, 2016 - Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today positive field trial results conducted in Israel from its Ag-biologicals program, which is currently focused on the development of Bio-stimulant products. In these tests, candidate microbial strains identified and predicted by Evogene for their ability to improve corn resistance to drought conditions, yielded positive efficacy and stability results in the first year of field testing.

Example: EVO-0685 - improved ear size and weight at harvest resulted with 17% increase of yield per plant

Path forward

Combination of microbial hits, additional testing along with product development activities (upscale, fermentation & formulation)

Novel Ag-Biologicals - upcoming value drivers

Novel Ag-Biologicals

Introduction ■

Table of contents

• Our technology .
• Applications and product programs
• · Summary of investment highlights

• 1 Unique technology platform, combining expertise in plant science and cutting-edge computational tools
• 2 Engine for next generation product development targeting multi-billion dollar ag markets
• 3 Innovation partner of choice for industry leaders
• 4 | Diversified product portfolio with multiple paths to milestone payments and royalties from commercialization
• Strong balance sheet 5

Thank you.

Contact: investors@evogene.com T: +972 8 931 1964